01—Abstract
Summary
Summary of the 10-K filed February 27, 2007. Cited figures are marked; the original filing is the authoritative source.
Charles River Laboratories International, Inc. reported net sales from continuing operations of $1,058.4 milliona for fiscal 2006, up 6.5% from $993.3 million in 2005, and operating income of $188.2 million, versus $184.7 million a year earlier.
The company reports two segments: Research Models and Services (RMS), with net sales of $515.0 millionb (48.7% of total), and Preclinical Services (PCS), which includes Phase I clinical services, with net sales of $543.4 million (51.3% of total, up 10.9%). Operating margin declined to 17.8% from 18.6%, mainly due to $11.7 million of stock option expense under SFAS 123(R). Net income was a loss of $(55.8) million in 2006, compared with net income of $142.0 million in 2005.
The result was driven by a $181.0 millionc loss from discontinued operations, which included a $129.2 million goodwill impairment tied to the sale of the Phase II-IV Clinical Services business for approximately $215 million in cash and the decision to close the Interventional and Surgical Services business. Income from continuing operations fell to $125.2 million, or $1.79 diluted per share, from $145.8 million, or $2.02, in 2005. Balance sheet and cash flow activity was dominated by expansion and capital returns.
Capital expenditures were $181.7 milliond in 2006, and the company projects $200 million to $225 million for 2007, with new preclinical facilities in Massachusetts and Nevada. Total debt rose to $572.1 million at December 30, 2006, from $296.1 million, after the issuance of $350.0 million of 2.25% convertible senior notes due 2013. The company also repurchased $250.0 million of treasury stock during 2006 and had $35.3 million remaining under its repurchase authorization at year-end.
02—Key points
Key Highlights
- Net sales from continuing operations rose 6.5% to $1,058.4 million in 2006, with PCS sales up 10.9% and RMS sales up 2.4%.
- Operating income was $188.2 million (17.8% of net sales), compared with $184.7 million (18.6%) in 2005, with the margin reduction attributed mainly to stock compensation expense.
- Net loss of $(55.8) million, reflecting a $(181.0) million loss from discontinued operations including a $129.2 million goodwill impairment on the Phase II-IV Clinical Services business.
- Income from continuing operations was $125.2 million, or $1.79 per diluted share, down from $145.8 million, or $2.02, in 2005.
- Capital expenditures were $181.7 million in 2006, with $200 million to $225 million planned for 2007 to expand preclinical and research model capacity.
- Total debt increased to $572.1 million from $296.1 million, driven by $350.0 million of 2.25% convertible senior notes due 2013.
- Share repurchases totaled $250.0 million of treasury stock in 2006, with $35.3 million remaining under the authorization as of year-end.
03—Questions
Frequently Asked Questions
Why did Charles River report a net loss in 2006 after earning $142.0 million in 2005?
The net loss of $(55.8) million was due mainly to a loss from discontinued operations of $(181.0) million. That loss included a $129.2 million goodwill impairment on the Phase II-IV Clinical Services business, which was sold for approximately $215 million in cash, along with a tax expense of $37.8 million related to the sale and results from the Interventional and Surgical Services business.
How did the company's core business segments perform in 2006?
Preclinical Services net sales grew 10.9% to $543.4 million, and its operating income rose to $82.3 million from $67.9 million. Research Models and Services net sales increased 2.4% to $515.0 million, but its operating income fell to $147.8 million from $159.8 million, with the operating margin dropping to 28.7% from 31.8%, mainly due to stock compensation expense, slower transgenic services, and lower large model sales.
What is the company's plan for capital spending and facility expansion?
The company spent $181.7 million on capital expenditures in 2006 and expects $200 million to $225 million in 2007. Key projects include the Nevada preclinical facility, which is expected to begin phased occupancy in mid-summer 2007, expansions in Ohio and Edinburgh, and an expansion of California research models capacity, with about half expected to open in the second quarter of 2007. The filing states that the company may be unable to build out these facilities as anticipated.
How did the company change its debt and capital structure during 2006?
The company issued $350.0 million of 2.25% convertible senior notes due 2013, with net proceeds of $343.0 million. It also entered a $428.0 million amended credit agreement, and total debt rose to $572.1 million at December 30, 2006, from $296.1 million a year earlier. Shareholders' equity fell to $1,595.2 million from $1,827.0 million, reflecting the share repurchases and the net loss.
Does the company pay dividends?
No. The company has not declared or paid cash dividends on its common stock in the past two years and does not intend to pay cash dividends in the foreseeable future. It intends to retain earnings to finance operations and expansion, and some covenants in its revolving credit and term loan agreements limit its ability to pay dividends.
04—Continue